{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"129","value":"329"},{"groupId":"OG001","spread":"95.0","value":"323"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"215"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"126","value":"413"},{"groupId":"OG001","spread":"123","value":"430"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"168"}],"units":"Participants"}],"title":"Cycle 3 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"215"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.","id":"OG000","title":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)"},{"description":"Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.","id":"OG001","title":"Arm C (Bevacizumab+Paclitaxel+Carboplatin)"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length=21 days)","title":"Cmax of Bevacizumab in Arm B and Arm C","type":"SECONDARY","unitOfMeasure":"mcg/mL"}